Literature DB >> 35273438

Coexistence of Positive 99mTc-DPD Scintigraphy and Monoclonal Gammopathy: A Frequent Challenge.

Ana Roteta Unceta-Barrenechea1,2, Jorge Melero Polo2,3, Alejandro Andrés Gracia1,2, Pablo Revilla Martí2,3, Sebastian Menao Guillén2,4, Carmen Lahuerta Pueyo2,4, Raquel Pérez-Palacios2, Inmaculada Moreno Gázquez2,4, Anyuli Gracia Gutiérrez2,5, Miguel Ángel Aibar Arregui2,6.   

Abstract

Background: Cardiac involvement is common in amyloidosis, and the vast majority of cases of amyloid cardiomyopathy are attributed to primary amyloidosis or transthyretin amyloidosis (ATTR). Although the coexistence of scintigraphy suggestive of ATTR with monoclonal gammopathy of undetermined significance is well documented, the correct diagnosis is still challenging in non-referral centers.
Methods: We performed a retrospective study reviewing all amyloid cardiomyopathy cases diagnosed at our center over the last 5 years, and described our experience and diagnostic approach.
Results: During the last 5 years, 74 patients with positive scintigraphy were identified. Of these patients, 41 were included in this study as they had all necessary tests for a complete diagnosis. Two of these 41 patients had variant ATTR and 29 had wild-type ATTR. Ten patients had monoclonal gammopathy (24.4%), and it was consequently impossible to obtain a specific diagnosis. During follow-up, 14 patients (34.1%), five of them from the monoclonal gammopathy group, died, reflecting the severity of disease. Conclusions: In patients with ATTR-suggestive scintigraphy, monoclonal gammopathy frequently occurs concomitantly, thus not allowing to establish a specific diagnosis. A biopsy could only be replaced by genetic testing in selected cases.

Entities:  

Keywords:  Amyloidosis; Cardiomyopathy; Monoclonal gammopathy; Transthyretin

Year:  2022        PMID: 35273438      PMCID: PMC8888328          DOI: 10.6515/ACS.202203_38(2).20210927A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  18 in total

1.  Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).

Authors:  Pooja Phull; Vaishali Sanchorawala; Lawreen H Connors; Gheorghe Doros; Frederick L Ruberg; John L Berk; Shayna Sarosiek
Journal:  Amyloid       Date:  2018-02-09       Impact factor: 7.141

2.  Diagnosis of genetic amyloidosis through the analysis of transthyretin gene mutation using high-resolution melting.

Authors:  Carmen Lahuerta; Sebastián Menao; Anyuli Gracia-Gutierrez; Esperanza Bueno-Juana; Natalia Guillén; Víctor Sorribas; Alejandro Andrés Gracia; Miguel A Aibar
Journal:  Int J Cardiol       Date:  2019-10-19       Impact factor: 4.164

Review 3.  Systemic amyloidosis.

Authors:  Ashutosh D Wechalekar; Julian D Gillmore; Philip N Hawkins
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

Review 4.  Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.

Authors:  Esther González-López; Ángela López-Sainz; Pablo Garcia-Pavia
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2017-09-01

Review 5.  The Prevalence and Management of Systemic Amyloidosis in Western Countries.

Authors:  Hans L A Nienhuis; Johan Bijzet; Bouke P C Hazenberg
Journal:  Kidney Dis (Basel)       Date:  2016-02-25

6.  Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.

Authors:  Merrill D Benson; Joel N Buxbaum; David S Eisenberg; Giampaolo Merlini; Maria J M Saraiva; Yoshiki Sekijima; Jean D Sipe; Per Westermark
Journal:  Amyloid       Date:  2019-01-07       Impact factor: 7.141

7.  A sporadic case of late-onset familial amyloid polyneuropathy with a monoclonal gammopathy.

Authors:  Ana Sofia Correia; Marcelo Mendonça; André Caetano; Elmira Medeiros
Journal:  Neuromuscul Disord       Date:  2015-05-27       Impact factor: 4.296

8.  Relationship between monoclonal gammopathy and cardiac amyloid type.

Authors:  Joseph J Maleszewski; David L Murray; Angela Dispenzieri; Martha Grogan; Naveen L Pereira; Sarah M Jenkins; Daniel P Judge; Patrizio Caturegli; Julie A Vrana; Jason D Theis; Ahmet Dogan; Marc K Halushka
Journal:  Cardiovasc Pathol       Date:  2012-10-24       Impact factor: 2.185

Review 9.  Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.

Authors:  Michelle M Kittleson; Mathew S Maurer; Amrut V Ambardekar; Renee P Bullock-Palmer; Patricia P Chang; Howard J Eisen; Ajith P Nair; Jose Nativi-Nicolau; Frederick L Ruberg
Journal:  Circulation       Date:  2020-06-01       Impact factor: 29.690

10.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Authors:  Julian D Gillmore; Mathew S Maurer; Rodney H Falk; Giampaolo Merlini; Thibaud Damy; Angela Dispenzieri; Ashutosh D Wechalekar; John L Berk; Candida C Quarta; Martha Grogan; Helen J Lachmann; Sabahat Bokhari; Adam Castano; Sharmila Dorbala; Geoff B Johnson; Andor W J M Glaudemans; Tamer Rezk; Marianna Fontana; Giovanni Palladini; Paolo Milani; Pierluigi L Guidalotti; Katarina Flatman; Thirusha Lane; Frederick W Vonberg; Carol J Whelan; James C Moon; Frederick L Ruberg; Edward J Miller; David F Hutt; Bouke P Hazenberg; Claudio Rapezzi; Philip N Hawkins
Journal:  Circulation       Date:  2016-04-22       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.